Background: Larynx cancer, a major upper respiratory tract malignancy, remains a global public health challenge, driven by smoking, alcohol use, and chronic inflammation, despite medical and public health advancements.
Methods: Data from the Global Burden of Disease 2021 study were used to assess larynx cancer mortality trends from 1990 to 2021 across global, regional, and national levels. Death rates, absolute mortality numbers, and Estimated Annual Percentage Change (EAPC) were calculated.
Results: Globally, the number of deaths from larynx cancer increased by 36.67% between 1990 and 2021, while death rates slightly declined, with an EAPC of -0.41. Males consistently accounted for the majority of deaths, with 100,393 deaths in 2021, though female mortality showed a larger percentage increase of 60.13% compared to 33.39% in males. Significant regional disparities were evident, with the highest death rates reported in Eastern Europe and Central Latin America, where countries like Bulgaria and Cuba recorded rates exceeding 6 per 100,000 population. In contrast, Oceania reported the lowest rates, below 0.5 per 100,000. The elderly (75 + years) experienced the largest increase in mortality, rising by 85.4%, while deaths among the 15-49 age group remained relatively stable. Additionally, larynx cancer death rates were correlated with SDI.
Conclusion: Despite slight declines in global death rates, the absolute burden of larynx cancer has increased due to population growth and aging. Regional disparities emphasize the need for targeted interventions and improved healthcare access. This study offers valuable insights for policy and resource planning.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887237 | PMC |
http://dx.doi.org/10.1186/s12957-025-03720-6 | DOI Listing |
Importance: Treating locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) involves any combination of surgery, radiation, and chemotherapy, followed by routine monitoring for local recurrence or distant metastases. Given the poor patient outcomes, a significant unmet clinical need for improved treatment options remains.
Objective: To evaluate efficacy and safety of maintenance atezolizumab in patients with LA SCCHN at high risk of disease progression after multimodal definitive treatment.
Adenoid cystic carcinoma (ACC) is a relatively uncommon tumor among head and neck cancers, with laryngeal involvement, typically subglottic, being exceptionally rare. While ACC usually originates in the salivary glands, its occurrence in the larynx is highly unusual. Laryngeal adenoid cystic carcinoma (LACC) is characterized by indolent growth, frequent perineural invasion, and a tendency for local recurrence.
View Article and Find Full Text PDFInt J Mol Sci
February 2025
Department of Clinical and Experimental Medicine, University of Foggia, Via Rovelli 50, 71122 Foggia, Italy.
Head and Neck Squamous Cell Carcinoma (HNSCC) is a heterogeneous group of malignancies with poor survival outcomes, particularly in advanced stages. Identifying prognostic biomarkers could help improve patient management. miR-375, a small non-coding RNA, has been shown to influence tumor growth and immune responses, making it a candidate biomarker.
View Article and Find Full Text PDFPerioper Med (Lond)
March 2025
First Hospital of Shanxi Medical University, Departent of Otorhinolaryngology, Head and Neck Surgery, Taiyuan, 030000, China.
Background: Few studies have been published on the cognitive function and its relationship with quality of life (QoL) in patients with laryngeal squamous cell carcinoma (LSCC) undergoing surgery.
Objective: This study aimed to assess the association between changes in cognitive function perioperatively with QoL among patients with LSCC.
Methods: This was a prospective study.
IUBMB Life
March 2025
Department of First Clinical Medicine, Shanxi Medical University, Taiyuan, China.
Laryngeal squamous cell carcinoma (LSCC) exhibits aggressive growth, frequent recurrence, and a notable resistance to existing treatments. Building upon prior discoveries that identified junctional adhesion molecule 3 (JAM3) as a critical tumor suppressor in LSCC, this study delves into the transcriptional regulation by upstream stimulatory factor 1 (USF1) and its implications for LSCC pathogenesis. Employing dual-luciferase assays and chromatin immunoprecipitation-quantitative polymerase chain reaction (ChIP-qPCR), we confirmed USF1's direct binding to the E-box within the JAM3 promoter, thereby enhancing JAM3 expression in AMC-HN-8 and FD-LSC-1 cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!